Equities

Balchem Corp

Balchem Corp

Actions
Basic MaterialsChemicals
  • Price (USD)181.00
  • Today's Change0.69 / 0.38%
  • Shares traded46.27k
  • 1 Year change+48.85%
  • Beta0.6654
Data delayed at least 15 minutes, as of Nov 22 2024 17:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

  • Revenue in USD (TTM)942.38m
  • Net income in USD121.54m
  • Incorporated1967
  • Employees1.30k
  • Location
    Balchem Corp5 Paragon DriveMONTVALE 07645United StatesUSA
  • Phone+1 (845) 326-5600
  • Fax+1 (845) 326-5742
  • Websitehttps://balchem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sensient Technologies Corp1.53bn88.73m3.27bn3.96k36.893.0322.042.142.092.0936.1825.510.75511.785.22386,782.104.385.974.976.8231.8932.465.807.861.475.650.373361.171.350.9847-33.71-8.6611.613.97
Huntsman Corporation5.99bn-105.00m3.39bn6.00k--1.0914.320.5669-0.6103-0.691934.7617.940.81445.307.28997,833.30-0.63935.49-0.82757.2313.8618.83-0.7856.700.82634.110.357238.26-23.83-4.28-103.79---5.987.89
Ashland Inc2.11bn199.00m3.66bn3.20k19.741.277.731.733.933.3242.2861.020.3652.467.28660,625.003.440.51733.740.578231.9831.819.411.531.33--0.3199218.67-3.56-0.32818.45---1.408.52
Scotts Miracle-Gro Co3.55bn-34.90m4.35bn2.50k----95.091.22-0.6865-0.686562.06-6.871.133.5714.77---1.110.2744-1.470.36126.2828.21-0.98240.25740.52371.941.211,446.550.03942.4090.82--14.653.43
Avient Corp3.21bn149.00m4.68bn9.30k31.621.9814.291.461.621.6334.8925.850.54295.957.12345,473.102.531.952.942.3532.6728.394.663.081.213.630.464986.26-7.481.75-8.45-2.479.467.18
Olin Corp6.48bn150.80m4.90bn7.33k34.122.387.410.75571.231.2353.7617.640.84576.317.38884,985.001.874.942.315.9012.0818.152.225.660.8212.040.580328.56-27.12-0.3278-65.327.01-9.330.00
NewMarket Corporation2.78bn430.55m5.15bn2.00k11.913.779.581.8545.0445.04290.34142.191.023.706.061,387,631.0015.8412.8318.3015.9130.8426.5015.5711.511.5010.570.44330.44-2.403.3439.0711.17-8.344.80
Arcadium Lithium PLC900.60m155.10m5.68bn2.91k18.630.901721.656.310.28340.28340.99575.860.14571.528.99309,590.902.86--3.32--50.0439.9619.6322.910.6474--0.0922--8.5214.8020.6921.1134.76--
Balchem Corp942.38m121.54m5.86bn1.30k48.434.9833.956.223.723.7228.8836.210.58895.267.55723,793.407.607.378.158.1134.4731.4412.9011.821.908.930.162822.11-2.117.463.016.9413.9510.94
Cabot Corp-100.00bn-100.00bn5.90bn4.27k--4.14----------26.24------------------------1.36--0.4176----------1.47--
Element Solutions Inc2.41bn265.80m6.92bn5.30k26.002.8316.172.871.101.109.9310.080.4784.625.21453,981.105.292.545.742.7841.5640.1611.066.032.777.080.439735.01-8.483.54-37.43--13.16--
FMC Corp4.17bn1.53bn7.28bn5.80k4.791.584.271.7512.1911.6033.2936.910.35971.541.53631,500.0013.187.9118.9811.4237.4342.5636.6517.011.092.960.467830.30-22.670.923270.3521.58-8.1720.99
Celanese Corporation10.48bn1.10bn8.20bn12.41k7.471.134.230.782410.049.9595.6866.570.40753.297.75844,399.704.3011.325.1814.1323.1925.7010.5621.090.7563.770.626217.3513.108.863.5210.3211.016.13
Mosaic Co11.46bn371.20m8.30bn10.35k22.950.70126.190.72451.131.1335.4837.150.49873.609.431,106,685.001.485.561.856.8615.4520.922.979.400.49052.300.253614.42-28.397.39-67.4919.918.0051.57
Data as of Nov 22 2024. Currency figures normalised to Balchem Corp's reporting currency: US Dollar USD

Institutional shareholders

54.27%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20244.57m14.04%
The Vanguard Group, Inc.as of 30 Sep 20243.82m11.76%
APG Asset Management NVas of 30 Sep 20242.77m8.52%
Wasatch Advisors LPas of 30 Sep 20241.36m4.17%
SSgA Funds Management, Inc.as of 30 Sep 20241.23m3.80%
Conestoga Capital Advisors LLCas of 30 Sep 20241.18m3.62%
Geode Capital Management LLCas of 30 Sep 2024928.90k2.86%
Geneva Capital Management LLCas of 30 Sep 2024779.87k2.40%
Dimensional Fund Advisors LPas of 30 Sep 2024605.67k1.86%
ClearBridge Investments LLCas of 30 Sep 2024405.86k1.25%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.